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Smallpoxsepox model employing the A/Ncr mouse strain is used to evaluate anti-
orthopoxvirus therapies. These infections mimic large droplet transmission and result in 100% mortality
within 7-10 dayswith as little as 1 PFU of ectromelia virus. Unlike the A/Ncrmodel, humans are less susceptible
to lethal respiratory infections with variola virus and monkeypox virus as demonstrated by their lower
mortality rates. In this study we show that a low dose intranasal infection of C57BL/6 mice results in 60-80%
mortality and bettermodels smallpox. Comparing CMX001 (HDP-cidofovir) efﬁcacy in the A/Ncr strain and the
C57BL/6 strain revealed that delayed treatment with CMX001 is more efﬁcacious at preventing severe disease
in the C57BL/6 strain. The increased efﬁcacy of CMX001 in C57BL/6 over A/Ncr following an intranasal infection
with ectromelia appears to be mediated by a stronger Th1 cell mediated response. Following footpad infection
we show that the C57BL/6 strain has earlier and more robust transcriptional activity, Th1 cytokine secretions,
antigenpresenting activity and IFNγ splenic CD8+ Tcell responses as compared to the A/Ncr strain. As a result of
the enhanced immune response in the C57BL/6 strain, non-lethal intradermal ectromelia infections can
therapeutically protect up to 3 days following a homologous, lethal intranasal infection – much like how
smallpox vaccination can protect humans for up to 4 days following intranasal variola infection.
Published by Elsevier Inc.IntroductionWe are currently faced with the potential use of natural or
recombinant variola virus (VARV) and monkeypox virus (MPXV) as
biological weapons, as well as the emergence of human monkeypox in
Africa (Mortimer, 2003a; Parker et al., 2007b). The majority of the
population have no protection against these viruses due to the cessation
of vaccination in the smallpox-free epoch (Parker et al., 2008).
Furthermore, a growing section of the community cannot be vaccinated
due to their immuno-compromised status (Baker et al., 2003; Bray,
2003). Currently, the only antiviral treatment for such diseases is
intravenous cidofovir (CDV) administration, which is limited by its
inherent nephrotoxicity and intravenous delivery method (De Clercq,
2002; Safrin et al., 1997). To address this, an orally bioavailable
hexadecyloxypropyl ester of CDV (CMX001) and ST-246 have has been
produced and are in phase 1/2 clinical trials (Buller et al., 2004; Kern et
al., 2002; Parker et al., 2008a; Quenelle et al., 2004, 2007; Yang et al.,
2005). CMX001 and ST-246 have demonstrated antiviral efﬁcacy against
a number of orthopoxviruses and CMX001 also has activity against a
number of viruses that encode their own DNA polymerase.).
nc.We have previously shown that delayed oral administration of
CMX001 can be used to treat a lethal mousepox infection in the A/Ncr
strain (Buller et al., 2004; Parker et al., 2008a). The mousepox model is
arguably the best small animalmodel for the evaluation of VARV/MPXV
therapeutics due, in part, to the low dose of virus required for a lethal
infection, which produces a disease course that accurately reﬂects the
progress of natural smallpox. The A/Ncr strain is susceptible to lethal
mousepoxwhen infected intranasally (IN) or intradermally via breaks in
the skin of the footpad (FP) with extremely low dose inoculums.
However, human respiratory infectionswith VARV orMPXV havemuch
lower mortality rates compared to that of the A/Ncr mousepox model
(Fenner et al., 1988; Parker et al., 2007b). Furthermore, healthy humans
infected with VARV via breaks in the skin have a greatly reduced
frequency of severe disease or mortality (approx. 0.5-1%). Therefore the
A/Ncr strain may be too susceptible to mousepox, making it difﬁcult to
fully evaluate the therapeutic efﬁcacy of candidate antivirals. For this
reasonwe tested the efﬁcacy of CMX001 in the C57BL/6 strain, which is
highly susceptible to lethal infections by the IN route but resistant
following infections through the FP route, similar to VARV in humans
(Schell, 1960). Here we show that the CMX001 therapeutic treatment
window is extended in the C57BL/6 strain compared to the A/Ncr, and
that the reason for this is likely to be the increased early magniﬁcation
of a Th1 biased cell mediated response and more efﬁcient antigen
presentation at the draining lymph node.
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The C57BL/6 strain is resistant to footpad ECTV challenges
To compare the relative susceptibilities of A/Ncr and C57BL/6
strains, groups of A/Ncr and C57BL/6 mice were infected IN (Figs. 1A
and B) or via the FP (Figs. 1C and D) routes with increasing ectromelia
(ECTV) doses ranging from 0.009 to 9000 PFU. All A/Ncr mice died
with a minimum of 0.9 and 0.09 PFU for IN and FP infections,
respectively (LD50=0.3 and b0.009 PFU, respectively). A minimum
dose of 900 PFU was required to kill all the C57BL/6 mice with an IN
challenge (LD50=90 PFU). The 90 PFU IN dose killed 50% of the mice.
The maximum dose of 9000 PFU was not sufﬁcient to kill any C57BL/6
mice with a FP infection (LD50N9000 PFU). These ﬁndings conﬁrmedFig. 1. The A/Ncr strain is more susceptible to ECTV than the C57BL/6 strain. Groups of A/Ncr a
IN route (A and B) and the FP route (C and D). Spleen, liver and lung tissues were titred from A
limit of detection is indicated by a dashed line.those of Schell who showed that the closely related C57BL strain was
susceptible to a lethal infection by the respiratory route but not by the
subcutaneous route (Schell, 1960). Tissue infectivity titres reﬂected
the relative susceptibilities of mouse strains to lethal infection
following FP inoculation with 1000 PFU (Figs. 1E and F). Virus was
detected in spleens and livers of A/Ncr mice from day 4 post-
infection (p.i.) and the titres increased until day 7. Conversely, we
found signiﬁcantly lower titres in the C57BL/6 tissues compared to
those in the A/Ncr and found that splenic and liver titres were absent
or reduced by day 6 p.i. The low titres in C57BL/6 tissues indicate
that this strain begins to respond and control the infection from very
early time points, possibly within the ﬁrst 24-48 hours. The
susceptibility of the C57BL/6 mouse to an IN challenge, but not to
a FP challenge, is reminiscent of variola infections in humans.nd C57BL/6 mice were infected with ECTV doses ranging from 0.009 to 9000 PFU via the
/Ncr mice (E) and C57BL/6 (F) mice on days 1-7 p.i. following a 100 PFU FP infection. The
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strain following intranasal infections
The cause of death in mice infected with ECTV is unknown, but
liver necrosis is a contributing factor. To compare the severity of
mousepox in each strain, we sacriﬁced groups of infected A/Ncr and
C57BL/6 mice everyday for 7 days following an IN infection. The
infectious dose of 1500 PFU was used to ensure both strains had 100%
mortality, thus, allowing us to dissect how each strain responded to a
lethal infection. Virus particles were detected in liver samples at 2 and
3 days p.i. in the A/Ncr (Fig. 2A) and C57BL/6 (Fig. 2B) strain,
respectively. On day 4 p.i. the A/Ncr liver had an average of almost
1×106 PFU/mg, the C57BL/6's liver did not reach a comparable level
until 5 days p.i.. Both strains demonstrated an increase in liver titres asFig. 2. C57BL/6 mice have reduced tissue titres and liver enzyme levels. On days 1-7 p.i., sp
intranasally infectedwith 1500 PFU. The limit of detection is indicated by a dashed line. ASTan
to 7 p.i. (E) The A/Ncr and C57BL/6 survival curves are shown (⁎ indicates Pb0.055).time increased following infection. Viral titers in the A/Ncr strain's
liver were almost 2 logs higher than that of the C57BL/6 on day 6 p.i.
(p=0.0115). As expected, high levels of virus were detected in the
spleens and lungs of both strains, but the A/Ncr strain consistently
achieved higher titres several days earlier than the C57BL/6 strain.
To better compare the severity of disease, we also measured blood
levels of AST and ALT as biomarkers of acute liver damage and hepatic
disease (Figs. 2C and D). We found that levels of AST and ALT in the
A/Ncr strain were signiﬁcantly elevated by day 6 p.i. compared to the
background control and corresponded closely with the average day of
death for the A/Ncr strain, which was 7.2±0.2 (Fig. 2E). The average
day of death for the C57BL/6 strain was 9.2±0.2; two days prior to this
the levels of AST and ALT were variably elevated. Similarly, data from
patients infected in the Midwestern United States MPXV outbreak ofleen, liver and lung tissue titres were calculated from A/Ncr (A) and C57BL/6 (B) mice
d ALT liver enzymes from A/Ncr (C) and C57BL/6 (D) bleeds weremonitored from days 1
14 S. Parker et al. / Virology 385 (2009) 11–212003 revealed that 50% and 59% of analysed individuals had
abnormally high AST and ALT levels, respectively (Huhn et al., 2005).
In previous studies, we found that ALT levels were less variable and
gave a better indication of the stage of disease compared to AST levels
(Parker et al., 2008b).
Efﬁcacy of delayed intervention with CMX001
Mousepox was less severe in C57BL/6 mice than A/Ncr mice at a
matched IN dose. To see if this difference resulted in an increased
therapeutic windowwe IN inoculated A/Ncr and C57BL/6 with 100 PFU
of ECTV, and treated mice on various days p.i. with a 10 mg/kg loading
dose followed by every-other-day dosing of 2.5 mg/kg of CMX001, a
hexadecyloxypropyl ester of cidofovir. Treatments were initiated on
days 0 to 6 p.i. All of the A/Ncr vehicle treated mice died by day 8 p.i.
compared to 60% of the C57BL/6 mice by day 11 (Figs. 3A and B). 100%
survival was observed in A/Ncr mice whose CMX001 treatment was
delayed until 2 days p.i. (P=0.008), 80% survival was achieved in A/Ncr
mice whose treatment was initiated immediately or was delayed until
days 3 and 4 (P=0.05)(Fig. 3A). Delaying intervention until 5 days p.i.Fig. 3. Efﬁcacy of intervention with CMX001. A/Ncr and C57BL/6 mice were infected with 10
survival curves are shown in A and B, weight change is shown in C and D, respectively. Veh ar
day 3 p.i; NI 6 vehicle are non-infected mice receiving vehicle at day 6 p.i. The numbers 1-resulted in 100% mortality in the A/Ncr strain. All treated C57BL/6 mice
survived even when treatment was delayed until 6 days p.i (Fig. 3B)
and had minimal weight-loss compared to the A/Ncr strain (Figs. 3C
and D). In comparison, all infected A/Ncr mice had signiﬁcant weight
loss, even in the group with no mortality (day 2) (Fig. 3C). In studies
where A/Ncr mice were inoculated with a low LD100 (2 PFU/mouse)
dose by the IN route, we never observed 100% CMX001 mediated
protection at 6 days p.i. (data not shown). Thus, we conclude that the
C57BL/6 strain responds better to CMX001 treatment compared to the
A/Ncr strain at an equivalent challenge dose, and the A/Ncr mousepox
model may understate the efﬁcacy of CMX001 as a human therapeutic.
The C57BL/6 strain upregulates TLR13 and CD55 expression in response
to a footpad infection
To determine the basis for the enhanced resistance of the C57BL/6
mouse to lethal infection, as compared to the A/Ncr strain, wemeasured
a number of components of the host immune response. First, as a
general measure of the early response to infection we monitored
changes in gene transcription levels in the popliteal lymph nodes (PLN)0 PFU of ECTV and treated with CMX001 starting on day 0 to 6 p.i. A/Ncr and C57BL/6
e infectedmice receiving vehicle; 3CMX001 are non-infectedmice receiving CMX001 on
6 indicate the day p.i. that therapy was initiated.
Table 1
Transcriptional changes in genes involved in innate immunity, signalling (MAPK), defence response and cellular defence response
Probe set ID Expression proﬁle Gene symbol Gene title Gene ontology and pathway
Innate immune response
(GO:0045087)
1457753_at B6 6↑ 12↑ 24↓ Tlr13 Toll-like receptor 13 Innate immune response/inﬂammatory response
1418762_at B6 24↓ Cd55 CD55 antigen Innate immune response/complement activation,
classical pathway
1455560_at AJ 6↓ 12↓ 24↓ Ecsit Signaling intermediate in toll
pathway (evolutionarily conserved)
Innate immune response/MAPK signaling pathway/
transcriptional regulation
MAPK signaling pathway
(KEGG:mmu04010)
(KEGG:mmu04010)
1453851_a_at B6 24↑ Gadd45g Growth arrest and DNA-damage-
inducible 45 gamma
Activation of MAPKK activity/apoptosis/interferon-gamma
biosynthetic process/T-helper 1 cell differentiation
1420895_at B6 24↓ Tgfbr1 Transforming growth factor,
beta receptor I
TGF-beta receptor signaling pathway/gene expression/
induction of apoptosis/negative regulation of apoptosis
1415834_at B6 24↓ Dusp6 Dual speciﬁcity phosphatase 6 MAPK signaling (phosphatase activity)
Defense response
(GO:0006952)
1457753_at B6 6↑ 12↑ 24↓ Tlr13 Toll-like receptor 13 Innate immune response/inﬂammatory response
1418762_at B6 24↓ Cd55 CD55 antigen Innate immune response/complement activation,
classical pathway
1422758_at B6 24↓ Chst2 Carbohydrate sulfotransferase 2 Carbohydrate (N-acetylglucosamine) metabolic process/
inﬂammatory response
1455560_at AJ 6↓ 12↓ 24↓ Ecsit Signaling intermediate in toll
pathway (evolutionarily conserved)
–
1427752_a_at AJ 6↑ 12↑ 24↑ Tcrb-J T-cell receptor beta, joining region Cellular defense response
1422188_s_at AJ 6↓ 12↓ 24↓ Tcrg-V3 T-cell receptor gamma, variable 3 Cellular defense response
1422189_x_at,
1450521_a_at
AJ 6↓ 12↓ 24↓ Tcrg-V4 T-cell receptor gamma, variable 4 Cellular defense response
Fig. 4. Changes in TLR13 and CD55 transcription in the PLN. Following a 1000 PFU FP
infection TLR13 (A) and CD55 (B) were the only innate immune genes from the C57BL/6
PLNs to change transcription levels compared to naïve controls (N). Transcription levels
were evaluated from infected PLNs at 6, 12 and 24 hours p.i. (⁎Pb0.003 and ¤PN0.05).
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strain/time interaction effects were analyzed in accordance with the 2-
way ANOVA model, thereby resulting in 10 simultaneous pair-wise
statistical comparisons (6 strain-matched/p.i. time and 4 p.i. time
matched/between-strain). Emphasis was placed on the 6 strain-
matched/p.i. time comparisons in order to determine the differential
gene expression proﬁles due speciﬁcally to ECTV infection and not due
to consistent baseline strain-speciﬁc transcript differences. Statistically
signiﬁcant differentially expressed genes were partitioned into 13
distinct, infection time course-speciﬁc co-expression groups: 9 C57BL/6
(80 genes in total) and 4 A/Ncr (22 genes in total) groups (Supplemental
table S1). Notably, therewas no overlap between the C57BL/6 and A/Ncr
groups, suggesting that the genetic responses enabling the C57BL/6 to
overcome a FP infection is completely absent in the A/Ncr strain. Of
particular interest was the innate immune response biological process
gene ontology (Table 1).We detected two differentially expressed genes
in the C57BL/6 response to ECTV infection which are involved in the
innate response: TLR13 (toll-like receptor 13) and CD55 (decay
accelerating factor, DAF). Overall, we found that the C57BL/6 strain
was more pro-active at adjusting transcriptional regulation than the A/
Ncr strain (Supplemental table 1).
In the C57BL/6 strain, the level of TLR13 signiﬁcantly increased
over the ﬁrst 12 hours p.i. but returned to below naïve levels by 24
hours p.i. However, TLR13 levels in the A/Ncr strain did not change
signiﬁcantly over the ﬁrst 12 hours but, similar to the C57BL/6 strain,
decreased signiﬁcantly below naïve levels by 24 hours p.i. (Fig. 4A).
Unfortunately, little is known about TLR13 in mammals, including its
ligands, adaptors and location; but, it is known that humans do not
have a homologue of TLR13 (Wu et al., 2008).
Unlike TLR13 levels, CD55 was only signiﬁcantly down regulated at
24 hours p.i. in the C57BL/6 strain. In contrast, the levels of CD55 did not
signiﬁcantly change at anyof the timepoints in theA/Ncr strain (Fig. 4B).
In the complement pathway, CD55 (also know as decay accelerating
factor, DAF) binds C3b, C4b, C3bBb and C4b2a to inhibit C3 convertase
formation andaccelerate its decay (Kameyoshi et al.,1989). This action of
CD55 prevents inappropriate activation of the complement arm of the
immune system. The failure of the A/Ncr strain to upregulate TLR13
within the ﬁrst 12 hours of infection and to downregulate CD55 by 24
hours p.i. may be important to its inability to recover from infection. In
the latter case, the non-reduction of CD55 in the A/Ncr strain might be
responsible for the A/Ncr's sensitivity due to failure of the activation of
the complement system – we are currently exploring this hypothesis.Cytokine responses at the PLN are different between the A/Ncr and
C57BL/6 strains
To further evaluate the innate immune response at the PLN we
measured the levels of 23 cytokines and chemokines at 6, 12, 24 and
48 hours following a 1000 PFU FP challenge. Three mediators
Fig. 5. Early cytokine changes at the PLN following infection. PLNs were harvested at 6,
12, 24 and 48 hours p.i. and 27 cytokines were monitored for changes. (A) IFNγ and (B)
Rantes (CCL5) increased more rapidly in PLNs from the C57BL/6 strain. (C) The level of
IL-9 remained constant in the C57BL/6 strain but was rapidly upregulated from 12 hours
p.i. in the A/Ncr strain (⁎Pb0.05 and ¤PN0.05).
Fig. 6. C57BL/6 and A/Ncr responder cells react differently to antigen presentation by
PLN cells. Antigen presenting cells (APCs) were incubated with CD3+ T cells taken from
(A) vaccinated C57BL/6 and A/Ncr mice; and (B) from the F1 progeny of a C57BL/6 X A/
Ncr cross (⁎Pb0.0035 and ¤PN0.05).
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24 and 48 hours p.i., compared to those of the A/Ncr strain (Fig. 5A).
In addition to elevated IFNγ, the C57BL/6 had a rapid increase in
Rantes (CCL5) as early as 6 hours p.i. After 6 hours p.i. the level of
Rantes continued to increase to signiﬁcantly higher levels, and more
rapidly than those of the A/Ncr strain at 12, 24 and 48 hours p.i.
(Fig. 5B). This chemotactic chemokine is responsible for recruitment
of T cells, eosinophils, basophils and NK cells (Kuna et al., 1992;
Maghazachi et al., 1994; Schall et al., 1990). Interestingly, Parker et al
have previously observed that NK cells are crucial for recovery from
mousepox and the trafﬁcking of IFNγ secreting NK cells to the PLN
peaks at 56 hours p.i. following an ECTV footpad infection in C57BL/
6 mice (Parker et al., 2007a).We found no signiﬁcant differences in the response of all other
cytokines from both strains except for the response of IL-9 in the A/Ncr
strain which increases from 12 hours p.i., in contrast, the C57BL/6's
levels of IL-9 do not change (Fig. 5C). The increase in IL-9 is suggestive
of a Th2 biased response (Spellberg and Edwards, 2001) in the A/Ncr
strain, this hypothesis is supported by the observation that A/Ncr mice
produce signiﬁcantly less IFNγ following an ECTV infection and do not
upregulate the Th1 cytokine Rantes to the same level as the C57BL/6
strain does (Figs. 5A and B). Indeed, previous studies have shown that
a distinct cytokine proﬁle is employed by the resistant C57BL/6 strain
that includes the upregulation of IFNγ and TNF in the PLN compared
to the susceptible BALB/c (Chaudhri et al., 2004).
The C57BL/6 strains responds to antigen presentation more efﬁciently
than the A/Ncr strain
In a number of diverse infectious disease models the C57BL/6
mouse has been shown to have radically different susceptibilities to
severe disease compared to other inbred mouse strains (Heinzel et al.,
1991; Wallace and Buller, 1985; Wu-Hsieh, 1989). In the ECTV model,
data have suggested that this resistance is based partly on a more
robust Th1 biased immune response (Chaudhri et al., 2004). To
determine if the C57BL/6 mouse was immunologically more respon-
sive than the A/Ncr strain, we evaluated the antigen presenting cells
(APCs) of the PLN at various times p.i.
We found that APCs from the C57BL/6 strain incubated with
splenic CD3+ T cells from vaccinated C57BL/6 mice generated
signiﬁcantly higher 3H-thymidine counts at 24, 48 and 72 hours p.i.
compared to the non-infected controls. In contrast, the 3H-thymidine
counts generated by incubating A/Ncr APCs with vaccinated splenic
A/Ncr CD3+ T cells were not signiﬁcantly different to the non-infected
controls at any time points (Fig. 6A).
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and C57BL/6 PLNs, we usedmemory splenic CD3+ Tcells taken from F1
vaccinated progeny of C57BL/6 X A/Ncr mice. APCs from the C57BL/6
mice induced signiﬁcant proliferation in the F1 CD3+ T cells compared
to the non-infected controls from 24 hours p.i. (Fig. 6B). APCs from the
A/Ncr strain also induced a lower, but statistically signiﬁcant, rise in
cellular proliferation from 12 hours p.i. (Fig. 6B). These data conﬁrm
that the PLN cells from the C57BL/6 strain induce better proliferation
of responder cells than those of the A/Ncr strain. Thus, a reason for
A/Ncr sensitivity to ECTV is likely to be a delayed, less robust immune
response at the lymph node draining the site of infection.
CD4+ and CD8+ T cells provide differing levels of IFNγ in both strains
The previous experiments measured early cytokine synthesis and
early APC function by the PLN that drains the site of infection. In order toFig. 7. CD4+ and CD8+ splenocytes release different levels of IFNγ. (A) Splenic cell counts in C5
p.i. A similar increase was not observed in the A/Ncr strain until 8 days p.i. (B) Infectivity
(MOI=0) CD8+ splenocytes from A/Ncr (C) and C57BL/6 mice (D) were harvested and tested fo
time points and tested for IFNγ production (E and F) (⁎Pb0.0037 and ¤PN0.1).compare the adaptive immune response, A/Ncr and C57BL/6 mice were
infectedwith 3000PFUof the attenuated EV-138 virus. This virus is non-
lethal to the A/Ncr strain following a FP infection, therefore enabling us
to measure immunologic changes that cannot be measured in the
rapidly lethalwild-typevirus (Fig.1C).We found that following infection
the C57BL/6's splenic cell count began to increase as early as 4 days p.i.;
however, an increase in the A/Ncr's splenic cell count was not detected
until 8 days p.i., indicating a slower immune response in this strain (Fig.
7A). Although the A/Ncr's spleen was slower to respond, we found that
its infectivity, as determined by plaque assay,was 3 logs higher than that
of the C57BL/6's at day 6 p.i. Moreover, infectious virus was found in the
A/Ncr's spleen at 8 days p.i., by which time the C57BL/6 had cleared all
splenic virus (Fig. 7B). A similar response was observed in liver samples
which consistently had infective titres 2-3 logs higher in theA/Ncr strain
compared to that of the C57BL/6 strain at days 6 and 8 p.i. (data not
shown). We also measured the number of IFNγ+ CD4+ and CD8+ T cells7BL/6 mice infectedwith 3000 PFU of an attenuated (EV138) virus increased from 4 days
titres in the spleens of A/Ncr and C57BL/6 mice. Infected (MOI=0.1) and non-infected
r IFNγ levels at days 4, 6, 8 and 10 p.i. CD4+ splenocytes were also harvested at the same
18 S. Parker et al. / Virology 385 (2009) 11–21in the spleen. By 6 days p.i. we found a signiﬁcantly large increase in the
number IFNγ+/CD8+ cells in the C57BL/6's spleen; conversely, we
found that the A/Ncr strain only had a small (2 logs lower than that of
the C57BL/6) but signiﬁcant increase in cell numbers from day 6 p.i.
(Figs. 7C and D). With regard to IFNγ+/CD4+ cells, we found that the A/
Ncr strain had a large increase in cells at day 8 and day 10. The C57BL/6
strain had small but signiﬁcant elevations compared to the A/Ncr at
days 6 and 8 (Figs. 7E and F); however, on a per cell basis the IFNγ being
generated by the C57BL/6's T cells is at least 10 fold in excess of the IFNγ
produced by the A/Ncr's T cells.
A delayed footpad infection therapeutically protects against an
intranasal challenge
The protective immune response induced in C57BL/6mice following
subcutaneous infections with ECTV suggest a prophylaxis/therapeutic
utility ﬁrst demonstrated in humans with variola. Skin inoculationwith
VARV (variolation) was the ﬁrst attempt of prophylaxis through
vaccination and yielded mortality rates of 0.5-1% versus 20-40% for
respiratory infections (Fenner et al., 1988). Anecdotal evidence suggests
that vaccinia vaccination against smallpox is efﬁcacious up to 4 days p.i.
(Mortimer, 2003b). Human MPXV infections also appear to be milder
following intra-dermal infection, although this may to be due to the
virus strain or other factors (Cunha, 2004; Reed et al., 2004; Sejvar et al.,
2004). To test if the C57BL/6 strain could be used tomodel the protective
therapeutic effect of vaccination we evaluated an ECTV FP infection forFig. 8. A footpad infection protects the C57BL/6 strain against a lethal IN challenge. Survival o
intranasal together; and FP+IN (24 h), footpad infection administered 24 hours before IN infe
IN followed by FP infections on days 0, 1, 2 and 3 p.i. are shown. (D) Weight changes.efﬁcacy against an ECTV IN infection. We found that 60% of mice
infected INwith a 600 PFU inoculumdied by day 13 p.i. and experienced
a maximum of 28±0.8% body weight-loss and scruffy coats – both of
which are indicative of disease (Figs. 8A and B). Mice infected via the FP
route (also 800 PFU) survived and had a maximumweight-loss of 3.3±
1.8%. Furthermore, we found that complete protection was conferred
whenmicewere IN infected 24 hours post FP infection. Indeed, all mice
survived even when infected via the FP and IN routes simultaneously,
although these mice lost the most weight.
Because simultaneous FP and IN infectionswere sub lethal, we next
investigated if a FP infection could confer resistance to an IN infection
in a post-exposure therapeutic manor. To address this, we infected
mice with 800 PFU of ECTV IN followed by 800 PFU FP inoculations on
days 0,1, 2 and 3 p.i.We found that the FP inoculations could protect all
mice up to the lastmeasured point of 3 days p.i. and that 80% of control
animals were dead by day 12 p.i. (p=0.02) (Figs. 8C and D). These data
suggest that post-exposure vaccination alone, as supported by other
studies, or coupled with post-exposure antiviral therapy, should be
considered as a therapeutic treatment for smallpox and/or human
monkeypox in immuno-competent individuals (Mortimer, 2003b;
Samuelsson et al., 2008; Paran et al, in press).
Conclusions
Taken together, our data reveal that the C57BL/6 strain has the
potential to more accurately model smallpox and human-monkeypoxf infected C57BL/6 mice: (NI, not infected; FP, footpad; IN, intranasal; FP+IN, footpad and
ction; are shown). (B) Weight-loss of indicated groups. (C) The survival of mice infected
19S. Parker et al. / Virology 385 (2009) 11–21compared to the A/Ncr strain. We conclude that the C57BL/6 mouse
strain could be beneﬁcial for testing CMX001 and other anti-
orthopoxvirus drugs, and for therapeutic evaluation of vaccines.
Comparing the kinetics and magnitude of various measures of the
immune response between the C57BL/6 and A/Ncr strain suggests a
basis for severe disease andmay provide insights into themechanisms
of susceptibility of humans to orthopoxvirus infections.
Our studies further support the hypothesis that Th1 biased
immune responses are associated with recovery from orthopoxvirus
infected mice. It has also been demonstrated that humans vaccinated
with vaccinia virus generate a Th1 biased response (Zaunders et al.,
2006). Thus, it is likely that a Th1 biased response is necessary for
recovery from human monkeypox or smallpox.
Materials and methods
Cells and virus
BSC-1 cells (ATCCCCL 26)were grown in Eagle'sminimumessential
medium (MEM) containing 10% fetal calf serum (FCS) (Hyclone III,
Logan, UT), 2 mM L-glutamine (GIBCO, Grand Island, NY), 100 U/ml
penicillin (GIBCO, Grand Island, NY), and 100 μg/ml streptomycin
(GIBCO, Grand Island, NY). A plaque-puriﬁed isolate of the MOS strain
of ECTV (ATCC VR-1374) designated MOS-3-P2, was propagated in an
African green monkey kidney cell line, BSC-1 (Chen et al., 1992). Virus
was puriﬁed through a sucrose cushion as described elsewhere (Moss,
1998). Virus infectivitywas estimated as described previously (Wallace
and Buller,1985). Brieﬂy, virus suspensionswere serially diluted in PBS
+1% Fetal Calf Serum (Fetal Clone II, HyClone), absorbed tomonolayers
for 1 hr at 37 °C, and overlaid with a suspension of 1% carboxyl methyl
cellulose in DMEM +5 % Fetal clone II. After 4 days at 37 °C, virus
plaques were visualized and virus inactivated by the addition to each
well of 0.5 ml of a 0.3% crystal violet/10% formalin solution. A
replication deﬁcient virus (EV-138) and a non-attenuated virus
encoding GFP (EV-GFP) were also used and puriﬁed as above.
Animals
Four to six week old female A/Ncr and C57BL/6 mice were obtained
from the National Cancer Institute, Frederick MD., housed in ﬁlter-top
microisolator cages and fed commercial mouse chow and water, ad
libitum. The mice were housed in an animal biosafety level 3 contain-
ment areas. Animal husbandry and experimental procedures were in
accordance with PHS policy, and approved by the Institutional Animal
Care and Use Committee. Each group consists of 5 animals. Each
experiment was repeated thrice in various combinations. Mice were
monitored everyday until 21 days p.i. and then on days 28, 35 and 42.
Antiviral compound
The CMX001 analogue of CDV was a gift from Chimerix Inc.,
(Durham, NC). CMX001was freshly prepared prior to each experiment
by dissolving the compound in sterile, distilled water. Drug was stored
at 4 °C.
Viral challenge and tissue assays
Mice were anesthetised with 0.1 ml/10 g body weight of ketamine
HCl (9 mg/ml) and xylazine (1 mg/ml) by intraperitoneal injections.
Anesthetised mice were laid on their dorsal side with their bodies
angled so that the anterior end was raised 45° from the surface; a
plasticmouse holderwas used to ensure conformity. ECTVwas diluted
in PBS without Ca2+ and Mg2+ to the required concentration and
slowly loaded into each nare (5 μl/nare) or the FP (10 μl total). Mice
were subsequently left in situ for 2-3 mins before being returned to
their cages.At indicated times following exposure to ECTV, groups of mice
were treated by gavage with 0.1 ml sterile, distilled water (placebo) or
water containing the desired concentration of CMX001. To determine
infectious viral titres, mice were sacriﬁced post challenge, and lung,
spleen, and liver tissues and nasal-wash were isolated. Tissue was
ground in PBS (10% w/v), frozen and thawed three times, and
sonicated for 20 seconds. Virus infectivity (PFU/ml) in tissue
homogenates was estimated by titration on BSC-1 monolayers.
Arithmetic means were calculated for PFU/ml values above the limit
of detection (1×102 PFU/ml). Remaining mice were observed for
clinical signs of disease (morbidity) and mortality. Moribund mice
were euthanized. LD50 values were calculated as described (Reed and
Muench, 1938).
Clinical chemistry assay
AST (aspartate aminotransferase) and ALT (alanine aminotransfer-
ase) analysis was executed on a Cobas Mira Plus Chemistry Analyser
(Roche Diagnostics) using a modiﬁed International Federation of
Clinical Chemistry method. The samples were diluted as needed to
provide adequate sample volume for analysis or to bring the results
within the linear range of the analyser.
Cell proliferation assay
Antigen presenting cells (APCs) from PLNs were removed from
infected or control animals and a single-cell preparation was made in
RMPI+0.1% β-mercaptoethanol (Gibco), hepes (cellgro), sodium
pyruvate (cellgro) and 10% FCS (Hyclone III). 1×104 irradiated cells
were plated in 96-well round-bottom plates (costar). Responder cells
were isolated from 5 week post-vaccination animals that had been
intradermally vaccinated in the ﬂank with a replication deﬁcient virus
(ECTV-M138). Single-cell preparations were prepared in pharm-lyses
(BD Pharmingen) as permanufacturer's instructions. CD3+ Tcells were
isolated by a pan T cell isolation (Miltenyibiotec) as per the
manufacturer's instructions. 1×105 CD3+ T cells were incubated with
APCs for 48 hours. Cultures were then pulsed with 1 μCi of 3H-
thymidine (MP Biomedicals,) for 12-16 hrs. The following day the cells
were harvested onto a ﬁlter mat using a cell harvester (TomTec) and
counts determined by a liquid scintillation counter.
Flow cytometry
Red blood cells were lysed with BD Pharm Lyse (BD Biosciences
Pharmingen) and resuspended in RPMI-1640 (BioWhiticker) with 10%
FCS (vida supra). 1×106 cells were blocked for 10 min with Fc Block
(BD Biosciences Pharmingen) and stained with the following
antibodies: Gr-1-FITC, CD11b-PerCP Cy5.5, CD3-APC 660, CD4-Paciﬁc
Blue 445, CD11c-PE-Cy7, CD8-AF700, CD55-PE 575, CD19-APC and
CD45-Paciﬁc Orange (all from BD Biosciences Pharmingen). Cells were
ﬁxed with 10% ultrapure formaldehyde (Polysciences Inc.) and
analysed using a BD LSR II ﬂowcytometer (BD Biosciences
Pharmingen).
Cytokine staining
Antigen presenting cells were generated by infecting naïve
splenocytes overnight at an MOI of 0 or 0.1. The cells were then
irradiated at 2500 rads, labelled with CFSE (BD Biosciences) and co-
cultured with responder populations overnight. Samples were
incubated for 4-6 hours with Golgi Plug (BD Biosciences), washed
with PBS-1% Fetal Clone II and stained for surface markers. The cells
wereﬁxedusingCytoﬁx (BDBiosciences). For intracellular staining, the
cells were washed twice in Permwash buffer (BD Biosciences) and
incubated with anti-IFNγ antibody. The cells were washed twice in
Permwash buffer and analyzed on the BD LSRII. Serum levels of IFNγ
20 S. Parker et al. / Virology 385 (2009) 11–21were detected using a mouse IFNγ Flex Set (BD Biosciences) and
assayed on the BD LSR II. Serum levels of cytokineswere detected using
mouse Flex Sets (BD Biosciences) as per manufacturer's instructions.
The serumwas diluted 1:4 in assay buffer prior to the addition of beads
and detection reagent then analyzed on the BD LSR II.
A Bio-plex cytokine assay kit (Bio-rad) was used, as per manufac-
turer's instructions, for tissue supernatant cytokine staining. 23
cytokines were analysed: IL-1α and β; IL-2, -3, -4, -5, -6, -9, -10; IL-
12p40 and IL-12p70; IL-13 and -17; G-CSF; GM-CSF; IFNγ; Eotaxin;
KC; MCP-1; MIP-1a and-1b, Rantes and TNFα.
Microarrays
Total RNAwas extracted from both PLNs using the RNeasy Mini Kit
(Qiagen Inc,) according to the manufacturer's guidelines. The total
RNA was qualiﬁed by running micro-capillary gels on RNA LabChips
using the Bioanalyzer 2100 (Agilent Technologies). The quality was
assessed by identifying the 18 s and 28 s ribosomal RNA bands to
ensure RNA integrity. The total RNA was then quantiﬁed using the
NanoDrop® ND-1000 Spectrophotometer (NanoDrop).
Global gene expression proﬁling of PLNs was performed using
GeneChip® Mouse Genome 430 2.0 Arrays (Affymetrix, Inc). PLNs from
the C57BL/6 and A/Ncr strains were extracted at naïve, 6, 12, and 24
hours p.i. (n=3). mRNA ampliﬁcation/labelling and chip washing/
hybridizationwas conducted according to the manufacturer's guidelines.
Data were normalized using accuracy/precision-optimizing gc-RMA
algorithms, accounting for probe GC content (Wu and Irizarry, 2004,
2005). A balanced 2-way ANOVA was used to assess gene expression
variability (FDR≤0.01) (Pavlidis, 2003; Reiner et al., 2003). Differentially
expressed genes were statistically analyzed for gene functional category
enrichment (i.e. Gene Ontology and Pathway) using the 2×2 Fisher's
Exact Test implemented in theweb-basedDAVIDplatform (Hosack et al.,
2003; Huang et al., 2007; Sherman et al., 2007).
Statistics
An unpaired two-tailed t-test was used to compare the means of
two groups of mice. P values below 0.05 were considered statistically
signiﬁcant. Mortality rates were compared using Fisher's exact test.
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